A functional M196R polymorphism of tumour necrosis factor receptor type 2 is associated with systemic lupus erythematosus: A case-control study and a meta-analysis

Annals of the Rheumatic Diseases

Volumn 66, Issue 3, 2007, Pages 320-324

  Horiuchi, Takahiko ^a   Kiyohara, Chikako ^a   Tsukamoto, Hiroshi ^a   Sawabe, Takuya ^b   Furugo, Isao ^c   Yoshizawa, Seiji ^d   Ueda, Akira ^e   Tada, Yoshifumi ^f   Nakamura, Tadashi ^g   Kimoto, Yasutaka ^a   Mitoma, Hiroki ^a   Harashima, Shinichi ^a   Yoshizawa, Shigeru ^h   Shimoda, Terufumi ^h   Okamura, Seiichi ⁱ   Nagasawa, Kohei ^f   Harada, Mine ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b ATOMIC BOMB SURVIVORS HOSPITAL   (Japan)

^c KITAKYUSHU MUNICIPAL MEDICAL CENTER   (Japan)

^d Department of Surgery   (Japan)

^e MIYAZAKI PREFECTURAL MIYAZAKI HOSPITAL   (Japan)

^f SAGA UNIVERSITY   (Japan)

^g Kumamoto Center for Arthritis and Rheumatology   (Japan)

^h FUKUOKA NATIONAL HOSPITAL   (Japan)

ⁱ NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR RECEPTOR 2;

ALLELE; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; ETHNICITY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; POPULATION RESEARCH; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS;

ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; POLYMORPHISM, GENETIC; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II;

EID: 34147198192     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2006.058917     Document Type: Article

References (42)

1. Tsao BP. The genetics of human systemic lupus erythematosus. Trends Immunol 2003;24:595-602.
2. Vandenabeele P, Declerq W, Beyaert R, Fiers W Two tumor necrosis factor receptors: structure and function. Trends Cell Biol 1995;5:392-9.
3. Aggarwal BB. Signaling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 2003;3:745-56.
4. Rudwaleit M, Tikly M, Khamashta M, Gibson K, Klinke J, Hughes G, Interethnic differences in the association of tumor necrosis factor promoter polymorphisms with systemic lupus erythematosus. J Rheumatol 1996;23:1725-8.
5. Wilson AG, Gordon C, di Giovine FS, de Vries N, van de Putte LB, Emery P, A genetic association between systemic lupus erythematosus and tumor necrosis factor alpha. Eur J Immunol 1994;24:191-5.
6. Hajeer AH, Worthington J, Davies EJ, Hillarby MC, Poulton K, Ollier WE. TNF microsatellite a2, b3 and d2 alleles are associated with systemic lupus erythematosus. Tissue Antigens 1997;49:222-7.
7. D'Alfonso S, Colombo G, Della Bella S, Scorza R, Momigliano-Richiardi P. Association between polymorphisms in the TNF region and systemic lupus erythematosus in the Italian population. Tissue Antigens 1996;47:551-5.
8. Jacob CO, McDevitt HO. Tumor necrosis factor-α in murine autoimmune 'lupus' nephritis. Nature 1988;331:356-8.
9. Theofilopoulos AN, Lawson BR. Tumor necrosis factor and other cytokines in murine lupus. Ann Rheum Dis 1999;58:149-55.
10. Aringer M, Zimmermann C, Graninger WB, Petera P, Steiner G, Ulrich W. TNF is an essential mediator in lupus nephritis. Arthritis Rheum 2002;46:3418-19.
11. Gaffney P, Kearns GM, Shark KB, Ortmann WA, Selby SA, Malmgren ML. A genome-wide search for susceptibility genes in human lupus erythematosus sibpair families. Proc Natl Acad Sci USA 1998;95:14875-9.
12. Shai R, Quismorio FP Jr, Li L, Kwon O, Morrison J, Wallace DJ. Genome-wide screen for systemic lupus erythematosus susceptibility genes in multiplex families. Hum Mol Genet 1999;8:639-44.
13. Komata T, Tsuchiya N, Matsushita M, Hagiwara K, Tokunaga K. Association of tumor necrosis factor receptor 2 (TNFR2) polymorphism with susceptibility to systemic lupus erythematosus. Tissue Antigens 1999;53:527-33.
14. Morita C, Horiuchi T, Tsukamoto H, Hatta N, Kikuchi Y, Arinobu Y. Association of tumor necrosis factor receptor type II polymorphism 196R with systemic lupus erythematosus in the Japanese. Molecular and functional analysis. Arthritis Rheum 2001;44:2819-27.
15. Al-Ansari AS, Ollier WER, Villarreal J, Ordi J, The L-S, Hajeer AH. Tumor necrosis factor receptor II (TNFRII) exon 6 polymorphism in systemic lupus erythematosus. Tissue Antigens 2000;55:97-9.
16. Takahashi M, Hashimoto H, Akizuki M, Sasazuki T, Nishikimi N, Ouchi H. Lack of association between the Met196Arg polymorphism in the TNFR2 gene and autoimmune diseases accompanied by vasculitis including SLE in Japanese. Tissue Antigens 2001;57:66-9.
17. Lee EB, Yoo JE, Lee YJ, Choi YJ, Park KS, Song YW. Tumor necrosis factor receptor 2 polymorphism in systemic lupus erythematosus: no association with disease. Hum Immunol 2001;62:1148-52.
18. Khoa PD, Sugiyama T, Yokochi T. Polymorphism of IL-10 promoter and tumor necrosis factor receptor II in Vietnamese patients with systemic lupus erythematosus. Clin Rheumatol 2005;24:11-13.
19. Till A, Rosenstiel P, Krippner-Heidenreich A, Mascheretti-Croucher S, Croucher PJP, Schafer H. The Met-196>Arg variation of human tumor necrosis factor receptor 2 (TNFR2) affects TNF-α-induced apoptosis by impaired NF-κB signaling and target gene expression. J Biol Chem 2005;280:5994-6004.
20. Barton A, John S, Ollier WE, Silman A, Worthington J. Association between rheumatoid arthritis and polymorphism of tumor necrosis factor receptor II, but not tumor necrosis factor receptor I, in Caucasians. Arthritis Rheum 2001;44:61-5.
21. Dieude P, Petit E, Cailleau-Moindrault S, Osorio J, Pierlot C, Martinez M. Association between tumor necrosis factor receptor II and familial, but not sporadic, rheumatoid arthritis: evidence for genetic heterogeneity. Arthritis Rheum 2002;46:2039-44.
22. Pierik M, Vermeire S, Steen KV, Joossens S, Claessens G, Vlietinck R. Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab. Aliment Pharmacol Ther 2004;20:303-10.
23. McDermott MF, Aksentijevich I, Galon J, McDermott EM, Ogunkolade BW, Centola M. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999;97:133-44.
24. Horiuchi T, Tsukamoto H, Mitoma H, Miyagawa H, Tamimoto Y, Yoshizawa SI. Novel mutations in TNFRSF1A in patients with typical tumor necrosis factor receptor-associated periodic syndrome and with systemic lupus erythematosus in Japanese. Int J Mol Med 2004;14:813-8.
25. Ida H, Kawasaki E, Miyashita T, Tanaka F, Kamachi M, Izumi Y. A novel mutation (T61I) in the gene encoding tumor necrosis factor receptor superfamily 1A (TNFRSF1A) in a Japanese patient with tumor necrosis factor receptor-associated periodic syndrome (TRAPS) associated with systemic lupus erythematosus. Rheumatology 2004;43:1292-9.
26. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1272-7.
27. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
28. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
29. Cochran WG. The combination of estimates from different experiments. Biometrics 1954;10:101-29.
30. Whitehead A, Whitehead J. A general parametric approach to the meta-analysis of randomized clinical trials. Stat Med 1991;10:1665-7.
31. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088- 101.
32. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple graphical test. BMJ 1997;315:629-34.
33. Douni E, Kollias G. A critical role of the p75 tumor necrosis factor receptor (p75 TNF-R) in organ inflammation independent of TNF, lymphotoxin α or the p55 TNF-R. J Exp Med 1998;188:1343-52.
34. Grell M, Douni E, Wajant H, Lohden M, Clauss M, Maxeiner B. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 1995;83:793-802.
35. Molokhia M, McKeigue P. Risk for rheumatic disease in relation to ethnicity and admixture. Arthritis Res 2000;2:115-25.
36. Tuchiya N, Kawasaki A, Tsao BP, Komata T, Grossman JM, Tokunaga K. Analysis of the association of HLA-DRB1, TNFalpha promoter and TNFR2 (TNFRSF1B) polymorphisms with SLE using transmission disequilibrium test. Genes Immun 2001;2:317-22.
37. Chodha S, Miller K, Farwell L Sacks S, Daly MJ, Rioux JD. Haplotype analysis of tumour necrosis factor receptor genes in 1p36: no evidence for association with systemic lupus erythematosus. Eur J Hum Genet 2006;14:69-78.
38. Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 2001;19:163-96.
39. Aringer M, Smolen JS. Complex cytokine effects in a complex autoimmune disease: tumor necrosis factor in systemic lupus erythematosus. Arthritis Res Ther 2003;5:172-7.
40. Aringer M, Graninger WB, Steiner G, Smolen JS. Safety and efficacy of tumor necrosis factor a blockade in systemic lupus erythematosus. An open-label study. Arthritis Rheum 2004;50:3161-9.
41. Aringer M, Smolen JS. Tumour necrosis factor and other proinflammatory cytokines in systemic lupus erythematosus: a rationale for therapeutic intervention. Lupus 2004;13:344-7.
42. Horiuchi T, Morita C, Tsukamoto H, Mitoma H, Sawabe T, Harashima S. Increased expression of membrane TNF-α on activated peripheral CD8+ T cells in systemic lupus erythematosus. Int J Mol Med 2006;17:875- 9.